- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
BREAKING NEWS: IBS Agent Tegaserod (Zelnorm) Is Pulled From Market
ROCKVILLE, Md. -- The FDA announced today that Novartis has agreed to withdraw Zelnorm (tegaserod), the only approved drug for irritable bowel syndrome (constipation), after a pooled analysis of 29 placebo-controlled, short-term trials found a small but statistically significant increase in ischemic events, including angina and stroke. The analysis identifed 13 such events, including one death, in more than 11,600 patients treated with tegaserod versus one event among a placebo group.
ROCKVILLE, Md., March 30 -- The FDA announced today that Novartis has agreed to withdraw Zelnorm (tegaserod), the only approved drug for irritable bowel syndrome (constipation), after a pooled analysis of 29 placebo-controlled, short-term trials found a small but statistically significant increase in ischemic events, including angina and stroke. The analysis identifed 13 such events, including one death, in more than 11,600 patients treated with tegaserod versus one event among a placebo group.
Duration of Use Guidance Published for Systemic Corticosteroids in Atopic Dermatitis Treatment
September 12th 2025The new position paper faults the absence of a clearly defined, evidence-based ceiling on duration of use for the persistent overuse of systemic corticosteroids for AD management.
